Skip to Content

Many Americans Have COVID-19 Vaccine Preferences

THURSDAY, April 29, 2021 -- Nearly three-quarters of Americans say they have a preference for a specific COVID-19 vaccine, a new survey finds.

The poll of 1,000 people found that most (36 percent) preferred Pfizer, followed by Moderna at 19 percent and Johnson & Johnson at 17 percent, CBS News reported.

Reasons cited for wanting the Pfizer vaccine include the vaccine's efficacy (45 percent), positive study data (35 percent), reportedly fewer side effects (32 percent), reading a positive news story (29 percent), and social media posts by family and friends (21 percent), according to the results of the survey by M Booth Health, a health communications consultancy, and Savanta, a market research and advisory company.

Among those who preferred the Moderna vaccine, common reasons included efficacy (32 percent), fewer side effects (31 percent), positive study data (30 percent), and social media posts by family and friends (23 percent), CBS News reported.

Those who wanted the Johnson & Johnson vaccine listed reasons such as the fact that it requires only one shot (31 percent), preexisting trust in the brand (26 percent), or "good experiences" with the company's products in the past (19 percent).

CBS News Article

© 2021 HealthDay. All rights reserved.

Read this next

AI System Can Predict Deterioration in COVID-19 Patients in ED

THURSDAY, May 13, 2021 -- An artificial intelligence (AI) system can predict deterioration of COVID-19 patients in the emergency department, according to a study published online...

Pfizer Vaccine Given Final Approval for Use in Adolescents

THURSDAY, May 13, 2021 -- In a decision that clears the way for schools to reopen safely next fall, U.S. health officials on Wednesday gave their final stamp of approval for the...

Neurological Manifestations Prevalent for Inpatients With COVID-19

THURSDAY, May 13, 2021 -- Neurological manifestations are common among patients hospitalized with COVID-19 and are associated with an increased risk for in-hospital mortality,...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.